CompletedInterventional · Phase 1NCT00967577 ↗177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
CompletedInterventional · Phase 2NCT01622868 ↗Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROGHani Lamie AshamallaPIInterventionOther: Laboratory Biomarker Analysis · Drug: Lapatinib Ditosylate · Radiation: Stereotactic Radiosurgery · Radiation: Whole-Brain RadiotherapyDatesDec 2012 – Dec 2019· Results postedSponsorNRG OncologyHER2-Positive Breast CarcinomaInvasive Breast CarcinomaMetastatic Malignant Neoplasm in the Brain+2 more
CompletedInterventional · Not applicableNCT01816776 ↗A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep ApneaJames E. IpPIInterventionDevice: Treatment Group (transvenous stimulation of the phrenic nerve) · Device: Control Group (Optimal Medical Therapy)DatesMar 2013 – Sep 2016· Results postedSponsorRespicardia, IncSleep Apnea, CentralSleep Disordered BreathingHeart Failure
CompletedInterventional · Phase 2NCT01936831 ↗The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive TuberculosisJean W. PapePIInterventionDrug: Isoniazid · Dietary supplement: Vitamin B6DatesAug 2014 – Sep 2021· Results postedSponsorNational Institute of Allergy & Infectious DiseasesTuberculosis
CompletedInterventional · Not applicableNCT02030418 ↗The LEADLESS II IDE Study (Phase I): Safety and Effectiveness Trial for the Nanostim Leadless PacemakerJames E. IpPIInterventionDevice: Leadless PacemakerDatesFeb 2014 – Jun 2015· Results postedSponsorSt. Jude Medical FoundationBradycardia
CompletedInterventional · Phase 1/2NCT02158858 ↗A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)Joseph M ScanduraPIInterventionDrug: Pelabresib · Drug: RuxolitinibDatesJul 2014 – Jan 2025· Results postedSponsorConstellation PharmaceuticalsMyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative Neoplasm+11 more
CompletedInterventional · Phase 2NCT02266745 ↗A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsScott T. TagawaPIInterventionDrug: PT-112 InjectionDatesJul 2014 – Aug 2024 (est.)SponsorPhosplatin TherapeuticsAdvanced Solid TumorsCRPCmCRPC+6 more
CompletedInterventional · Not applicableNCT02274844 ↗Improving Medication Adherence in the Alabama Black BeltMonika M SaffordPIInterventionBehavioral: Living Well with Diabetes ProgramDatesApr 2016 – Jan 2019· Results postedSponsorPatient-Centered Outcomes Research InstituteDiabetes MellitusMedication Adherence
CompletedInterventional · Phase 3NCT02278718 ↗A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) TreatmentJames J. GallagherPIInterventionDrug: NexoBrid · Procedure: Standard of CareDatesMay 2015 – Apr 2021· Results postedSponsorMediWound Ltd.Thermal Burns
CompletedInterventional · Phase 1NCT02290951 ↗An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy (ELM-1)John AllanPIInterventionDrug: Odronextamab multiple dose levelsDatesJan 2015 – Aug 2025SponsorRegeneron Pharmaceuticals, Inc.Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
CompletedInterventional · Phase 4NCT02299414 ↗A Pragmatic Multicenter Randomized Clinical Trial (RCT) of Antihypertensive Therapy for Mild Chronic Hypertension During Pregnancy: Chronic Hypertension and Pregnancy (CHAP) ProjectPhyllis AugustPIDaniel W SkupskiPIInterventionDrug: Anti-hypertensive therapy · Other: No anti-hypertensive therapy (unless BP is severe)DatesJun 2015 – Apr 2022· Results postedSponsorUniversity of AlabamaHypertension
CompletedInterventional · Phase 2NCT02365649 ↗A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Upadacitinib (ABT-494) for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyAliza B SolomonPIInterventionDrug: Placebo · Drug: ABT-494DatesMar 2015 – Nov 2016· Results postedSponsorAbbVie Inc.Crohn's Disease
CompletedInterventional · Phase 3NCT02518594 ↗A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short CervixDaniel W SkupskiPIInterventionDrug: Vaginal progesterone · Drug: Placebo · Device: Arabin PessaryDatesNov 2015 – Dec 2024· Results postedSponsorEunice Kennedy Shriver National Institute of Child Health and Human DevelopShort Cervical Length
CompletedInterventional · Phase 4NCT02519777 ↗A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIVMarshall J. GlesbyPIInterventionDrug: Placebo for maraviroc (MVC) · Drug: Placebo for dolutegravir (DTG) · Drug: Dolutegravir (DTG) · Drug: Maraviroc (MVC)DatesApr 2016 – Dec 2019· Results postedSponsorNational Institute of Allergy & Infectious DiseasesHIV Infections
CompletedInterventional · Not applicableNCT02528500 ↗Early Feasibility Assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch VesselsPeter ConnollyPIInterventionDevice: GORE® EXCLUDER® Thoracoabdominal Branch EndoprosthesisDatesNov 2015 – May 2016· Results postedSponsorW.L. Gore & Associates, Inc.Thoracoabdominal Aortic Aneurysm
CompletedInterventional · Phase 2/3NCT02635009 ↗Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung CancerHani Lamie AshamallaPIInterventionRadiation: Three-Dimensional Conformal Radiation Therapy · Radiation: Intensity-Modulated Radiation TherapyDatesDec 2015 – May 2023· Results postedSponsorNRG OncologyExtensive Stage Small Cell Lung CarcinomaLimited Stage Small Cell Lung Carcinoma
CompletedInterventional · Phase 1/2NCT02649790 ↗A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients With Newly Diagnosed and Relapsed/Refractory Cancer IndicationsGail J RobozPIInterventionDrug: KPT-8602 · Drug: ASTX727 · Drug: DexamethasoneDatesJan 2016 – Aug 2024SponsorKaryopharm Therapeutics, Inc.Relapsed/Refractory Multiple Myeloma (RRMM)Metastatic Colorectal Cancer (mCRC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
CompletedInterventional · Phase 2NCT02807272 ↗A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: TipifarnibDatesJan 2017 – Nov 2020· Results postedSponsorKura OncologyLeukemia, Myelomonocytic, Chronic
CompletedInterventional · Phase 2NCT02859558 ↗Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune ResponsesTimothy WilkinPIInterventionDrug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapyDatesJan 2017 – Dec 2020· Results postedSponsorAIDS Clinical Trial GroupHIV-1 Infection
CompletedInterventional · Phase 2NCT02952534 ↗TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination DeficiencyCora SternbergPIInterventionDrug: RucaparibDatesFeb 2017 – Jul 2021· Results postedSponsorClovis Oncology, Inc.Metastatic Castration Resistant Prostate Cancer